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Abstract Blood pressure is a way of describing the end result
of changes in cardiac output, intravascular volume and periph-
eral resistance. It has certain advantages in that it is a reproduc-
ible and easily measured parameter, but in itself, it offers only a
limited understanding of the underlying haemodynamics. In
pregnancy, profound haemodynamic changes occur and in hy-
pertensive diseases of pregnancy defining a condition by blood
pressure alone risks missing the underlying cause. Partly, this
has been a problem of ascribing the cause of hypertensive syn-
dromes to the placenta which has inhibited rigorous research
into other possible causes of haemodynamic dysfunction. It is
becoming increasingly evident that hypertension in pregnancy
may be associated with primarily high cardiac output or high
peripheral resistance. A knowledge of the underlying type of
hypertension may allow more rational treatment of these con-
ditions in pregnancy rather than therapeutic attempts at control-
ling blood pressure by any means possible as an end in itself.
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Introduction
Hypertension in Pregnancy: Definitions and History
Hypertension in pregnancy remains a ‘cinderella area’ of path-
ophysiology in clinical obstetrics. For many decades—and
still now—the acute pathological changes that compromise
the maternal cardiovascular system during pregnancy with
possible devastating tissue and organ dysfunction remained
firmly rooted to the nineteenth century criteria of high blood
pressure and proteinuria, both ‘tertiary, downstream features
of the disease’ [1]. The profusion of names for this condition,
pre-eclampsia, toxaemia, gestosis and proteinuric pregnancy
induced hypertension, underline the task of understanding
such a condition whose diagnosis is based purely on the easily
measurable manifestations of complex, possibly distinctly dif-
ferent causes of high blood pressure in pregnancy.
Let us consider the very name pre-eclampsia, literally a dis-
ease that occurs prior to eclampsia (‘προ-ἐκλαμψία’, ‘before-
sudden occurrence’). This term was introduced by Johannes
Varandaeus in the year 1620 treatise ‘Tractatus (of gynaecology)
de affectibus Renum et Vesicae’. More than one century later,
proteinuria was described in relation to fluid accumulation during
pregnancy resulting in acute fits and possibly death if the fetus
and placenta are not delivered. Pierre Rayer (1793–1867), a
Frenchman, was the first to describe proteinuria in eclamptics,
cited in his then classic text ‘Diseases of the Kidney’ [2]. It took a
few more years for Scipione Riva-Rocci’s mercury manometer
(1896) to be introduced and allowed to recognize that pre-
eclampsia was a hypertensive disorder. It is surprising that in
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2017, this condition is still classified according to Varandeus-
Rayer and Riva Rocci. It is tempting to speculate that the
consequences of defining hypertensive disorder according to
such arcane criteria (ICD-10 code 014) have prevented a rational
categorization of the condition based on cause, not effect.
But names and definitions are important. Indeed,
some guidelines include almost everything from head-
ache to liver damage to disseminated intravascular co-
agulation; intra uterine growth restriction (IUGR) plus
hypertension qualifies for pre-eclampsia (PE) even with-
out proteinuria. Broader names better fit broader criteria.
We opt here for considering all these conditions within
the collective term hypertensive disorders of pregnancy
(HDP). The definition of HDP covers pregnancy in-
duced hypertension, otherwise known as gestational hy-
pertension (GH), all conditions of GH associated with
maternal and foetal complications, among which can
occur a typical renal glomerular lesion that causes pro-
teinuria, and chronic hypertension (CH) (existing prior
to pregnancy).
The ‘Trophoblast Invasion’ Aetiological Theory
In 1975, Brosens I and Renaer M [3] published a key paper on
‘The pathogenesis of placentae infarcts in preeclampsia’. These
concepts were later developed by Khong TY, De Wolf F,
Robertson WB and still among the authors, Brosens [4]. In this
latter work, pathologic findings on pre-eclamptic placentae
were associated with small-for-gestational-age infants. This
particular link between shallow trophoblastic invasion in early
gestation, placental insufficiency, led to a focused scientific
insight into this possible origin of maternal endothelial dysfunc-
tion and hypertension associated with IUGR. The link between
such characteristics of poor placental development in the first
trimester and ‘preeclampsia’ occurring early in gestation asso-
ciated with IUGR was reviewed by Burton, Woods, Jauniaux
and Kingdom in 2009 [5]. Doppler interrogation of uterine
arteries has for three decades been widely studied as a possible
proxy of these pathological changes occurring in early placental
development: foetal growth and maternal hypertension [6–8].
Unfortunately, the theory [8], molecular [9] and his-
topathological [5] had hardly developed scientifically in
30 years and has persuaded many to consider this clin-
ical phenotype the sole cause of pre-eclampsia by those
that uncritically accepted association as equivalent to
causation. Time at onset of the clinical signs and
symptoms (before and after 34 weeks of gestation) be-
came the criterion on which to define its severity.
‘Consequently, PE could be considered as a single path-
ophysiological entity with a wide spectrum of severity
manifested in gestational age at which delivery becomes
necessary for maternal and/or foetal indication’ [10].
This interpretation of pre-eclampsia is in striking
contrast with epidemiological, pathological and clinical
evidence and has arguably held up the proper under-
standing of the origin of both hypertensive disease and
fetal growth restriction which are frequently closely
related.
Pathophysiology and Clinical Phenotype: Towards a New
Definition
Apparently anomalous characteristics of the condition
are that whilst in early onset pre-eclampsia, birthweight
is reduced, at term the condition is associated with nor-
mal or large weight babies [11–13, 14•]. Other possible
explanations—for example underlying cardiovascular
dysfunction or metabolic syndrome—do not contradict
the relationship between early placental shallow tropho-
blast invasion and subsequent maternal endothelial dam-
age. They do however suggest a different clinical phe-
notype of pre-eclampsia where maternal risk factors ap-
pears to play a predominant role, and both placental and
newborn weight appears to be normal or even large.
The existence of two main placental diseases had been
recently reviewed by Redman and Staff [15]. Both pla-
cental lesions, early shallow trophoblastic invasion and
late villi crowding generate a similar oxidative stress
that damage the maternal endothelium that magnify un-
derlying maternal risks; these might be so severe as to
require delivery prior to 34 weeks of gestation [16].
The obvious limitation of current definitions is that
irrespective of the type of hypertension, women with
identical systolic pressures are considered the same as
each other, when their haemodynamics (cardiac output,
stroke volume, heart rate, vascular resistance and arterial
function) may be significantly different. Importantly, all
recent studies [17–21] on maternal haemodynamics sug-
gest profound differences from normal pregnancies in
cardiac output, vascular resistance and arterial function
depending on the type of pregnancy hypertension and
the gestation at which it occurs. The fundamental prob-
lem is that hypertension itself is characterized as the
problem rather than the manifestation of an underlying
cardiovascular dysfunction.
In the clinical arena, the ongoing debate on how to re-
classify and interpret pre-eclampsia might be summarized by
the recently published Co-Lab statement: ‘Despite intensive
study, we have not been able to improve the management or
early recognition of preeclampsia…. It is possible that within
the syndrome, there may be different phenotypes with patho-
genic pathways that differ between the subtypes. The capacity
to recognize and to exploit different subtypes is of obvious
importance for prediction, prevention, and treatment’ [22].
These strong statements that challenge the validity of the long
trial of knowledge accumulated on pre-eclampsia were
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anticipated in 2010 by Steegers and co-workers on a review
paper on the Lancet [23]: ‘Poor early placentation is especially
associated with early onset disease (of pre-eclampsia before
34 weeks of gestation). Predisposing cardiovascular or meta-
bolic risks for endothelial dysfunction,…, might dominate in
the origins of late onset pre-eclampsia (after 34 weeks of
gestation).’
Cardiovascular Function and Pre-eclampsia
Cardiac output (CO) increases during pregnancy and
plateaus in the late second and early third trimester,
1.5 L/min (31%) above non-pregnant values [24•]. At
28 weeks of gestation, the percentage of total maternal
CO to the uterus is approximately 12% [25•]. This in-
crease is sustained both by the increasing heart rate
(HR) and stroke volume (SV). Multiparity and
multifetal pregnancies significantly influence these indi-
ces. Diastolic blood pressure shows a decrease that al-
ready starts in early first trimester and extends until the
late second trimester [24•]. Total vascular resistance
(TVR) decreases until the early second trimester. As a
consequence, we usually observe a decrease in diastolic
blood pressure. Mean arterial pressure (MAP) starts to
increase towards term as compared to non-pregnant da-
ta. In this adaptation process, the venous system in-
creases in venous capacitance, due to enhanced venous
distensibility, and mostly the splanchnic system accom-
modates the normal plasma volume expansion [26•]. A
recent meta-analysis calculated an average increase in
plasma volume of 45.6% [27•].
Cardiovascular remodelling involves the heart itself. The
left ventricular mass (LVM) increases to values 30–40%
above non-pregnant values with a concentric hypertrophy
since the first two trimesters of pregnancy [28•]. This dramatic
increase outperforms that achieved only by exercise by ath-
letes, who might gain 25% eccentric remodelling [28•]. The
left atrial diameter is already significantly enlarged during the
first weeks of pregnancy [29•, 30•].
It is plausible that a case of pre-eclampsia that occurs earlier
in gestation and is associated with fetal growth restriction is
related to low cardiac output and high peripheral vascular
resistance [31] with a much similar profile as observed in
women with fetal growth restriction without HDP [32]. In
cases of later and term gestation pre-eclampsia, babies tend
to be larger and there is a predominantly high cardiac output,
low peripheral vascular resistance and raised intravascular
volume state [33]. Certainly, the clinical phenotype of a very
‘dry’, intravascularly depleted woman at 26 weeks with a
growth restricted baby and conversely of a well-perfused
oedematous woman with a bounding pulse and large baby at
38 weeks rings true: both have hypertension, but the mecha-
nisms may be diametrically opposite.
Implications for Pharmacotherapy
It is plausible to consider that if these diametrically
opposed cardiovascular states both cause hypertension,
then the pharmacological treatment for one condition
will not necessarily cure the other. Beta blockers, com-
bined alpha and beta blockers, calcium antagonists, ad-
renergic false transmitters, presynaptic alpha receptor
modulators, nitrates and diuretics have all been used to
treat hypertensive pregnancy. International guidelines
(NICE, ACOG) have in recent years supported a sim-
plification of the therapeutic options which in the UK
favour labetalol as a first line agent, with alpha methyl
dopa as second line, a place for calcium antagonists and
almost no place for diuretics. An inherent difficulty is
that though these agents have quite different modes of
action, they are used interchangeably. Further, national
guidance is based on little data: studies of hypertensive
agents of the scale performed in the general adult pop-
ulation do not exist hence empirical advice is given on
the basis of what seems to be safe clinical practice and
unlikely to harm the foetus. The major problem is that
hypertension per se is considered to be the goal of
therapy, irrespective of the underlying cause. The recent
CHIPS study [34] investigated whether ‘tight’ blood
pressure control conferred a benefit in outcome in wom-
en with hypertension in pregnancy, concluding that it
did not. Would it not have been instructive in determin-
ing benefit to understand the underlying differences in
womens’ cardiovascular status and in this light the re-
sponse to treatment?
Contrast this approach with rapidly evolving specialist
adult hypertensive practice. Knowledge of whether the con-
dition is ‘high output’ or ‘high resistance’ allows selection
of the anti-hypertensive agent that will work in the most
physiological way—not by targeting blood pressure—but
more the underlying condition [35, 36]. Non-invasive de-
vices, now readily available and validated in pregnancy, give
accurate cardiac output and other data and allow profiling of
arterial function in hypertension [37]. In a low cardiac out-
put, high vascular resistance scenario, a negatively inotropic
alpha/beta blocker such as labetalol may make the
haemodynamics worse whilst achieving the therapeutic goal
of lowering blood pressure; a calcium channel blocker may
be far better. In the well-perfused term, woman with hyper-
tension and a high cardiac output, labetalol and a diuretic
may be therapeutically better suited than a vasodilator—
where there is already vasodilatation. It may also be that
similar to anti-hypertensive therapy in the general popula-
tion, prescription of the ‘wrong’ drug for the haemodynamic
abnormality present may, due to physiological responses to
treatment, make women more likely to be resistant to sub-
sequent therapies. This is not to mention the fetal-placental
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unit, where a reduction in perfusion might have serious
consequences.
Conclusions
The current therapeutic approach, a ‘one size fits all’, is cer-
tainly too simplistic: why not tailor therapeutic approaches to
haemodynamic profile rather than blood pressure alone? It is
now timely to define hypertensive conditions in pregnancy
based on the cardiovascular profile, treat women and perform
studies based on rational assessment of pharmacological ac-
tion—not purely of anti-hypertensive efficacy.
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